Enanta Pharmaceuticals | ENTA - Operating Expenses


Enanta Pharmaceuticals reported $126.59M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Gilead Sciences USD 3.95B 19.57B Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Halozyme Therapeutics USD 193.34M 1.15M Jun/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Immunic USD 23.33M 2.67M Dec/2025
Incyte USD 973.64M 4.65B Jun/2026
Insmed USD 526.79M 20.55M Jun/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
J&J USD 17.83B 388M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Ligand Pharmaceuticals USD 55.1M 20.75M Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Novartis USD 10.2B 912M Jun/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026